-
Bayer: Essure Permanent Birth Control Device Removal From US Market Is “Business Decision”
Or Is This Really An Essure Recall Due To High Numbers Of Adverse Events Reported To FDA And Related Essure Lawsuits (Posted by Tom Lamb at DrugInjuryWatch.com) We have reported developments concerning…
-
Pradaxa-Related Liver Injury: Health Canada’s Drug Safety Review Of Pradaxa Concludes There Is A Link
Remains Unknown Whether Pradaxa Label Change About Liver Damage In Canada Will Be Followed By Similar FDA Action In US (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2018 Health Canada announced…
-
Gadolinium Toxicity Risks Higher For Children, Pregnant Women, And People Receiving Multiple Doses
Gadolinium Deposition Disease And Neurological Adverse Reactions Associated With The Use Of Gadolinium-Based Contrast Agents (Posted by Tom Lamb at DrugInjuryWatch.com) In May 2018 Health Canada announced the results of its second…
-
Gout Drug Uloric Recall By FDA Requested In June 2018 Public Citizen Petition Letter
Consumer Group Contends That The Evidence Of Harmful Uloric Side Effects Outweighs Any Real Benefit To Patients (Posted by Tom Lamb at DrugInjuryWatch.com) The FDA should order Takeda Pharmaceuticals to immediately withdraw from…
-
Gadolinium-Based Contrast Agents: Gadolinium Retention Higher For Linear Gadolinium Agents Than Macrocyclic Agents
Gadolinium Retention Can Cause Various Medical Problems With General Diagnosis Label Of Gadolinium Deposition Disease (Posted by Tom Lamb at DrugInjuryWatch.com) There are two types of gadolinium based contrast agents (GBCAs): linear and…
-
Rexulti Warnings For Compulsive Behavior And Impulse Control Problems Added To Drug Label
FDA: Patients Using Rexulti At Risk For Experiencing Intense Urges For Gambling And Inability To Control Conduct (Posted by Tom Lamb at DrugInjuryWatch.com) Rexulti® (brexpiprazole) was initially approved by the FDA in…
